- Total revenue reached €384 million, up 7.7% (organic growth)
- Companion animal segment grew nearly 10%, leading overall performance
- Key petcare areas: dental, mobility, ear care, and endocrinology
- North America saw standout growth of over 20%
- New Thyronorm product boosted endocrinology sales
- Full-year growth outlook remains unchanged
Virbac reported a strong start to 2026, with first-quarter revenue reaching €384 million and organic growth of 7.7%. Growth was balanced across the business, but companion animal (petcare) products stood out with a 9.9% increase.
Petcare Drives Growth
The company’s petcare segment was the main growth engine, supported by strong demand across several key categories: dental care, mobility (joint health), ear treatments, and endocrinology (hormone-related conditions).
A major contributor was Thyronorm, a treatment for thyroid conditions, which Virbac recently added to its portfolio. This helped boost growth in endocrinology across multiple regions.
North America Leads, Europe Steady
North America delivered the strongest performance, with growth exceeding 20%, driven largely by petcare products and the rollout of Thyronorm.
Europe saw more modest growth (around 2%), but petcare remained strong—especially in pet food, dermatology, and ear care.
Other international markets also performed well, particularly in Latin America and parts of Asia, contributing to overall momentum.
Focus on High-Growth Pet Categories
Virbac continues to invest in what it calls its “Supercharge” platforms—key product areas with high demand in pet health. These include dental, mobility, and endocrinology, all of which showed strong double-digit growth.
Outlook for 2026
The company maintained its full-year guidance, expecting revenue growth between 5.5% and 7.5%. Leadership expressed confidence in continued momentum, supported by strong petcare demand and ongoing product innovation.
Information sourced from the company’s press release.
